Brief: Maat Pharma To Present Preclinical Data On AI-Generated Immunotherapy Product

Maat Pharma SA

31/10/2023 17:08

Oct 31 (Reuters) - Maat Pharma SA  MAAT.PA :
    * MAAT PHARMA TO PRESENT PRECLINICAL DATA AT SITC ON
MAAT034, AN
ARTIFICIAL INTELLIGENCE-GENERATED PRODUCT AIMED AT IMPROVING
PATIENTS’ RESPONSES TO IMMUNOTHERAPIES
    * PRESENTATION OF AI-BASED SCREENING STRATEGY DEVELOPED TO
IDENTIFY A NEW GENERATION OF DRUG CANDIDATES, MAAT034 BEING
FIRST PRODUCT FROM NEW RANGE
    * PRESENTATION OF IN VITRO DATA FOR MAAT034, PRODUCT
DEMONSTRATING
BIOLOGICAL ACTIVITY ENHANCING RESPONSES TO IMMUNE CHECKPOINT
INHIBITORS (ICIS) THERAPIES
    * FIRST-IN-HUMAN TESTING IS PLANNED FOR 2025, WITH FIRST
CLINICAL
BATCHES TO BE PRODUCED IN 2024

Source text for Eikon:  urn:newsml:reuters.com:*:nBwbYY4CGa
Further company coverage:  MAAT.PA 

 (Gdansk Newsroom)
 ((gdansknewsroom@thomsonreuters.com; + 48 58 7785110;))